The Trade

ELDN at $2.85. Enterprise value $82M. The market is pricing ≈29% probability that FDA accepts a non-inferiority Phase 3 design for tegoprubart in kidney transplant. We think it's 60%. 12-month expected value: $4.20, +47%. Size: 1% starter, scale to 3% on the binary.

The edge source is specific: FDA approved belatacept (Nulojix) in 2011 on exactly this data pattern — non-inferior composite, higher rejection rate, better safety and renal function. The market sees "missed primary endpoint" and prices a damaged asset. We see a precedented regulatory path at a 31-point probability discount.

The Drug and the Data

Eledon Pharmaceuticals has one drug, 33 employees, and no revenue. Tegoprubart is an anti-CD40L antibody designed to replace tacrolimus in kidney transplant immunosuppression.

Tacrolimus has been standard of care for 30 years. It works. It also gives 17% of transplant patients new-onset diabetes, gives 25% tremor, and is nephrotoxic — the drug keeping your transplanted kidney alive slowly destroys it. Every nephrologist knows this. Nobody has replaced it. Belatacept tried but carries a black-box PTLD risk and an EBV restriction that limits its patient pool. Tacrolimus remains king by default.

The first generation of anti-CD40L antibodies killed patients with blood clots. Tegoprubart was re-engineered to eliminate Fc-gamma receptor binding. In 127+ patients: zero thromboembolic events. Class risk resolved.

Phase 2 BESTOW trial. ≈120 patients, tegoprubart vs tacrolimus, head-to-head. Primary endpoint: eGFR superiority at 12 months.

Primary endpoint missed. eGFR 69 vs 66. Numerically better. Not statistically significant.

The safety data was not close:

Diabetes from 1-in-6 to 1-in-50. Tremor from 1-in-4 to 1-in-60. Categorically different.

The cost: rejection rate was higher — 20.6% vs 14.1% biopsy-proven. The FDA composite endpoint (death + graft loss + rejection, 20% non-inferiority margin) showed 22% vs 17%. Non-inferior.

Stock went from $4.60 to $1.35. Now $2.85.

Why the Market Is Wrong

The market sees a failed Phase 2. We see a precedented regulatory path.

In 2011, FDA approved belatacept for kidney transplant on BENEFIT trial data showing: non-inferior composite survival, superior eGFR (+10 mL/min at 3 years), and a 56% higher acute rejection rate vs cyclosporine. FDA accepted the trade-off — more rejection for better safety and renal function. ELDN's BESTOW data is structurally identical: non-inferior composite, numerically better eGFR, higher rejection, dramatically better safety.

Management knows this. They describe the composite endpoint as "historical approvable" and expect FDA to require ≈300 patients with 12 months of data, consistent with belatacept's Phase 3 scale. FDA guidance meeting expected Q2-Q3 2026.

The 24-month extension data reinforces the trajectory: eight patients, zero rejection, zero graft loss, eGFR improving from 67 to 74.2. That's the opposite of what tacrolimus does over time — it preserves kidneys instead of slowly poisoning them. Small N, right direction.

Is this edge accessible to everyone? Technically yes — anyone can look up belatacept's approval. In practice, micro cap biotech investors aren't transplant regulatory historians. The synthesis requires connecting an $82M EV company to a 15-year-old BMS approval. That's cross-silo work most participants skip.

The competitive moat amplifies this. ELDN is functionally alone. The only CD40L competitor in kidney transplant is Tonix (TNXP) with a 5-patient investigator-initiated Phase 2 at Mass General — 2-3 years behind a completed 127-patient randomized trial. Novartis tried the receptor side (anti-CD40) with iscalimab and discontinued after failing in both kidney and liver transplant. The receptor approach failed; the ligand approach showed activity. Different target, different result.

Meanwhile Sanofi, Biogen, and Amgen are all running Phase 3 CD40L programs in autoimmune disease, validating the biology without competing in transplant. Nobody wants this market except ELDN. It's too small for large pharma, too complex for most biotechs, and the first-gen safety failure scared everyone else off. If tegoprubart works, ELDN owns the space for years.

The Free Option in T1D

University of Chicago investigators running a tegoprubart-based islet cell transplant trial for Type 1 diabetes: 6 out of 6 patients achieved insulin independence, first three insulin-free at 1+ year, zero serious safety events. ELDN supplies the drug but doesn't fund the trial.

The context that makes this matter: Vertex's zimislecel — the leading stem cell-derived islet therapy — requires tacrolimus immunosuppression and killed two patients from immunosuppression toxicity. One cryptococcal meningitis, one severe dementia. Tegoprubart eliminates the safety liability that killed Vertex's patients. Partner play, not priced in.

The Bear Case

The primary endpoint missed. Not a technicality. In a superiority design, eGFR was not statistically significant. The composite non-inferiority is a secondary analysis. The headline is the headline, and the market priced it.

Rejection rate was higher. 20.6% vs 14.1%. Belatacept was approved with higher rejection too — and belatacept's commercial uptake has been modest (≈$500M peak sales). FDA may approve the pattern; clinicians may not adopt it. Transplant doctors are conservative. Trading 6 points of rejection for better metabolic outcomes is an intellectual argument that may not win at the bedside.

Phase 3 is vaporware. No FDA meeting scheduled. No protocol. No endpoint agreed. The 10-K says they'll "seek guidance" in 2026. Until an 8-K announces an actual FDA meeting outcome, Phase 3 exists in management discussion only.

The capital structure is hostile. 75.4M shares + 51.8M warrants = 127M fully diluted. 40% overhang. Four raises in 2023-2025. Phase 3 costs $150-300M+ on $133M in cash. Another raise is near-certain. Every rally gets sold into by warrant holders looking to exit.

The composite non-inferiority is unverified. BESTOW was designed as a superiority trial. Whether the composite non-inferiority (22% vs 17%, 20% margin) was pre-specified or post-hoc is unknown — the full publication with p-values hasn't appeared. If this was a post-hoc reframe, it weakens the regulatory argument considerably.

Scenarios and Sizing

85% idiosyncratic volatility. The thesis lives or dies on one factor: FDA Phase 3 design acceptance (≈40% of variance, ≈60% of our edge). The rest is capital structure drag (no edge), clinical data (public), and biotech beta (irrelevant at 85% idio). ≈32% of total variance in factors where we have informational advantage — concentrated, not diversified.

Bull (60%): FDA accepts non-inferiority composite. Phase 3 path de-risked, stock re-rates to $5.00-6.50. FD market cap reprices to $600-800M for a Phase 3-ready asset with no competition. Capital raise at premium validates. Target: $5.75.

Base (20%): Delay or ambiguity. FDA meeting pushed, conditional guidance. Stock drifts $2.00-2.75. Cash burns at $15M/quarter. Target: $2.38.

Bear (20%): FDA demands superiority. Non-inferiority rejected. Need to win on eGFR — the endpoint ELDN already missed. Phase 3 becomes prohibitively expensive. Stock to cash value minus burn. Target: $1.38.

EV = 0.60 x $5.75 + 0.20 x $2.38 + 0.20 x $1.38 = $4.20
Expected return: +47.4%
Market-implied P(bull): ≈29%
Our P(bull): 60%
Edge: 31 points on the regulatory binary
10th pctile path: -65% ($1.00)

Entry: $2.85 is acceptable. Prefer $2.00-2.50 on pullback — stock is +35.7% in the past month, above the 200-day MA at $2.57. The November offering at $1.65 was the better entry. Avoid above $3.50 where asymmetry compresses.

Size: 1% starter. Single-binary thesis with moderate edge = half-Kelly max of 3.8% GMV. Scale to 2-3% if FDA accepts non-inferiority. Cut immediately if FDA demands superiority.

Catalysts: FDA Type B meeting (Q2-Q3 2026) is the binary. Earnings May 13 for timeline update. BESTOW full publication for statistical rigor. Watch for insider open-market buying — directors got equity grants at $2.85 in January, BVF Partners bought $4.6M at $2.40 in May 2024, but no management buying with their own money.

Conviction

60/40 with 2:1 asymmetry is a bet you take. The safety data is real, the competitive moat is real, the regulatory precedent is direct, and the T1D option is free. The endpoint missed, the rejection rate was higher, and the capital structure punishes you for holding. That's why it's cheap. Size for the structure, not the feeling. 1% starter, scale on the binary.

Evidence